94 related articles for article (PubMed ID: 18607998)
1. Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts.
Nakagawa T; Otsuki N; Masai Y; Sasaki R; Tsukuda M; Nibu K
Acta Otolaryngol; 2008 Aug; 128(8):936-40. PubMed ID: 18607998
[TBL] [Abstract][Full Text] [Related]
2. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
3. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
4. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
5. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
Harada K; Kawaguchi S; Supriatno ; Onoue T; Yoshida H; Sato M
Oral Oncol; 2004 Aug; 40(7):713-9. PubMed ID: 15172641
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Yamagata S; Nakata B; Hirakawa K
Oncol Rep; 2004 Nov; 12(5):973-8. PubMed ID: 15492780
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
9. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Nukatsuka M; Fujioka A; Nakagawa F; Oshimo H; Kitazato K; Uchida J; Sugimoto Y; Nagayama S; Fukushima M
Int J Oncol; 2004 Dec; 25(6):1531-6. PubMed ID: 15547687
[TBL] [Abstract][Full Text] [Related]
10. A potential important role for thymidylate synthetase inhibition on antitumor activity of fluoropyrimidine and raltitexed.
Kabeshima Y; Kubota T; Watanabe M; Saikawa Y; Nishibori H; Hasegawa H; Kitajima M
Anticancer Res; 2002; 22(6A):3245-52. PubMed ID: 12530071
[TBL] [Abstract][Full Text] [Related]
11. Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma.
Harada K; Ferdous T; Yoshida H
Oncol Rep; 2007 Nov; 18(5):1077-83. PubMed ID: 17914556
[TBL] [Abstract][Full Text] [Related]
12. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
You MH; Kim WJ; Shim W; Lee SR; Lee G; Choi S; Kim DY; Kim YM; Kim H; Han SU
J Gastroenterol Hepatol; 2009 Aug; 24(8):1393-400. PubMed ID: 19486256
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
Tachimori A; Yamada N; Amano R; Ohira M; Hirakawa K
Anticancer Res; 2008; 28(2A):629-38. PubMed ID: 18507001
[TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Taguchi T; Yoshida T; Toth G
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():144-9. PubMed ID: 16897991
[TBL] [Abstract][Full Text] [Related]
15. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anticancer agent (S-1) and radiation.
Harada K; Kawaguchi S; Supriatno ; Onoue T; Yoshida H; Sato M
Int J Oncol; 2004 Oct; 25(4):905-11. PubMed ID: 15375539
[TBL] [Abstract][Full Text] [Related]
17. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
[TBL] [Abstract][Full Text] [Related]
18. [The possibility of S-1 for the treatment of patients with urological cancers].
Akaza H
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():236-8. PubMed ID: 16898009
[TBL] [Abstract][Full Text] [Related]
19. [Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet].
Tsujimoto H; Tsukioka S; Koizumi K; Nakagawa F; Uchida J; Sugimoto Y; Oka T; Fukushima M; Watanabe T
Gan To Kagaku Ryoho; 2007 Mar; 34(3):413-8. PubMed ID: 17353633
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of concurrent chemoradiotherapy with S-1 plus nedaplatin for hypopharyngeal cancer].
Kobayashi S; Shimane T; Egawa S; Ono T; Mori T; Kamakazu K; Sanbe T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):233-5. PubMed ID: 21368486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]